Skip to main content
Caplight Logo









GlyTR Therapeutics

GlyTR Therapeutics

Private
Irvine, CaliforniaHealthcare & Life Scienceshttps://glytrtherapeutics.com/

Last Round

Grant

Sep 10, 2025

Total Funding Raised

$8.65M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

GlyTR Therapeutics is a biotechnology company developing a new class of anti-cancer immunotherapeutic molecules and CAR-T cells.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

cancer immunotherapyCAR-T cell therapybispecific proteinstumor-associated carbohydrate antigensTACAlectin bindingoncology biotechprecision medicinedrug discoveryglycobiologysolid tumor therapynext-gen immunotherapybiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GlyTR Therapeutics Comparables

Compare GlyTR Therapeutics with similar companies based on industry and business-model similarity.

GlyTR Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
GO Therapeutics
83%
Tacalyx
79%
Saccharo
79%

GlyTR Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantSep 10, 2025
GrantFeb 21, 2025
GrantOct 10, 2023
Series AOct 22, 2018
GrantSep 18, 2018
Accelerator
May 17, 2016

Key People

Founding team and executive leadership

Robert Genthert

Interim Chief Executive Officer

Executive Team

GlyTR Therapeutics Investors

Notable investors and investment history

GlyTR Therapeutics investors
InvestorRounds
National Cancer InstituteGrant
NIH RADxGrant
EvoNexusAccelerator
California Institute for Regenerative MedicineGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2026

    Monthly visitors grew 388% MoM, reaching 1.1K.

  • Sep 10, 2025

    $464K grant round completed.

GlyTR Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

GlyTR Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about GlyTR Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersIrvine, California
Employee Range2
Year Founded2015
Last FundingSep 10, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?